(0.27%) 5 145.25 points
(0.27%) 38 546 points
(0.38%) 17 914 points
(-0.75%) $83.22
(1.35%) $1.949
(-0.17%) $2 343.10
(1.11%) $27.56
(0.65%) $928.10
(-0.26%) $0.932
(-0.21%) $11.00
(-0.36%) $0.798
(0.87%) $92.68
-4.33% SEK 0.0928
Live Chart Being Loaded With Signals
Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis, multiple sclerosis, and treatments for virally induced acute respiratory disorders...
Stats | |
---|---|
Volumen de hoy | 1.15M |
Volumen promedio | 739 347 |
Capitalización de mercado | 9.14M |
EPS | SEK0 ( 2024-02-23 ) |
Próxima fecha de ganancias | ( SEK0 ) 2024-05-10 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -0.220 |
ATR14 | SEK0.00100 (1.08%) |
Cyxone AB (publ) Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Cyxone AB (publ) Finanzas
Annual | 2023 |
Ingresos: | SEK0 |
Beneficio Bruto: | SEK-2.54M (0.00 %) |
EPS: | SEK-0.220 |
FY | 2023 |
Ingresos: | SEK0 |
Beneficio Bruto: | SEK-2.54M (0.00 %) |
EPS: | SEK-0.220 |
FY | 2022 |
Ingresos: | SEK6.40M |
Beneficio Bruto: | SEK4.16M (64.98 %) |
EPS: | SEK-0.430 |
FY | 2021 |
Ingresos: | SEK0.00 |
Beneficio Bruto: | SEK0.00 (0.00 %) |
EPS: | SEK-0.429 |
Financial Reports:
No articles found.
Cyxone AB (publ)
Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis, multiple sclerosis, and treatments for virally induced acute respiratory disorders. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and Covid-19 infections; and T20K, a Phase 1 candidate drug for the treatment of multiple sclerosis. The company was incorporated in 2015 and is based in Malmö, Sweden.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico